Skip to main navigation Skip to search Skip to main content

Cost-benefit of stockpiling drugs for influenza pandemic

  • Ministry of Health, Israel
  • Ben-Gurion University of the Negev

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.

Original languageEnglish
Pages (from-to)1280-1282
Number of pages3
JournalEmerging Infectious Diseases
Volume11
Issue number8
DOIs
StatePublished - Aug 2005
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Cost-benefit of stockpiling drugs for influenza pandemic'. Together they form a unique fingerprint.

Cite this